Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semuloparin
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
Semuloparin is an ultra-low-molecular-weight heparin (ULMWH) with a molecular weight of 2000–3000 daltons, consisting of a polydisperse mixture of oligomeric heparin fragments. It acts as an indirect inhibitor of factor Xa and factor IIa (thrombin) by binding to antithrombin III, accelerating its activity and inhibiting coagulation factors. Semuloparin was developed primarily for the prevention of venous thromboembolism (VTE) in patients at increased risk, such as those undergoing major orthopedic surgery or receiving chemotherapy for cancer. Compared to classical low molecular weight heparins, it has lower anti-thrombin activity and acts mainly on factor Xa, which may reduce the risk of bleeding. The drug was developed by Sanofi (formerly sanofi-aventis), but development has been discontinued following withdrawal from regulatory submission after Phase III trials[1][3][5][6][7].
- Brand names
- MulsevoOctaparinOctaparineVisamerin
- Other names
- semuloparin sodium
02
Targets
ATIII (Antithrombin III)
Beyond the preview
Go deeper on semuloparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semuloparin.